Clinical Trial Update: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for AU-007, a monoclonal antibody that binds IL-2 and inhibits IL-2Rα binding, being studied in unresectable locally advanced or metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• AU-007

Snippet

Sponsor: Aulos Bioscience, Inc. | Conditions: Advanced Solid Tumor, Metastatic Cancer | Phase 1, Phase 2 | Status: RECRUITING